Generic Medicine Info
Indications and Dosage
Prophylaxis of allergic conjunctivitis
Adult: As 0.1% ophthalmic solution: Instill 1-2 drops into the affected eye(s) 4 times daily.
Child: >3 yr: As 0.1% ophthalmic solution: Instill 1-2 drops into the affected eye(s) 4 times daily.

Allergic rhinitis
Adult: Usual dose: 5 mg bid.
Child: 1-4 yr: 1.25 mg bid; 5-10 yr: 2.5 mg bid.

Chronic asthma
Adult: Usual dose: 10 mg bid.
Child: 1-4 yr: 2.5 mg bid; 5-10 yr: 5 mg bid.
Special Precautions
Not for treatment of contact lens-related irritation. Contact lens should be removed prior to drug admin and reinserted only at least 10 minutes after application. Safety and efficacy have not been established in children <3 yr. Pregnancy and lactation.
Adverse Reactions
Headache, rhinitis, cold/flu symptoms, bronchitis, cough, sinusitis, sneezing/nasal congestion. Ocular application: Burning, dry eye, foreign body sensation and ocular discomfort.
Description: Pemirolast is a mast cell stabiliser that inhibits the in vivo Type I immediate hypersensitivity reaction. It inhibits chemotaxis of eosinophils into the ocular tissue and blocks the release of mediators. It is also reported to prevent calcium influx into mast cells following antigen stimulation. It has also been used in the treatment of chronic asthma and prophylaxis of allergic rhinitis.
Onset: Ocular application: A few days.
Excretion: Elimination half-life: 4.5 hr. About 10-15% is excreted in urine.
Store at 15-25°C.
MIMS Class
Antiasthmatic & COPD Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
Disclaimer: This information is independently developed by MIMS based on Pemirolast from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in